Navigation Links
China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
Date:7/28/2010

ass="xn-money">$930,000 to the Company's consolidated revenue in fiscal year 2010.

"In terms of retail footprint expansion, we deploy a two-pronged strategy which involves acquisitions and opening new stores," said Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT. "We believe this complementary approach is particularly effective. It enables us to establish our footprint in key locations by opening our own retail stores and allowing us to build upon existing sales of the stores we acquire by utilizing our renowned brand name."

About China BCT

China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries, Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited, each located in Guangxi province, China. The Company operates a large regional retail network in Guangxi province, consisting of 137 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network. For more information, please visit http://www.china-bct.com

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown ris
'/>"/>

SOURCE China BCT Pharmacy Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
(Date:12/15/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive six-month interim ... to evaluate once-weekly TransCon Growth Hormone in children ... analysis consists of 25 patients, representing approximately 50% ... completing all six months of treatment. ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Biofuels Key Issues in 2008, NEW YORK, Dec. ... and developments in biofuels are some of the issues,addressed ... The Outlook is produced annually by the Food ... analysis covering all of,the major sectors throughout the food ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient ... investigating the intratumoural,delivery of REOLYSIN(R) in combination ... A total of 23 patients received a ... REOLYSIN(R) at escalating dosages up to a,maximum ...
... Pharmaceuticals,LLC, a clinical stage drug-development company commercializing,first-in-class ... that enhances,oxygen diffusion, today announced that one ... recently recognized as a co-inventor of the ... alpha), a,erythropoiesis stimulating agent (US Patent No. ...
Cached Biology Technology:Rabobank Releases Annual North American Food & Agribusiness Outlook 2Rabobank Releases Annual North American Food & Agribusiness Outlook 3Rabobank Releases Annual North American Food & Agribusiness Outlook 4Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial 2Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics 2
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... is a metaphorical example of the perfect invasion by a ... a deserted island in the Galapagos Archipelago, the first cancer ... through many generations to establish itself as an invader of ... like any newly stabilized species in different ecological niches, cancer ...
... at Pacific Northwest National Laboratory have developed a ... meet or exceed current and emerging defense and ... Quartz Laser Photo-Acoustic Sensing, or "QPAS," is now ... PNNL, a Department of Energy national laboratory, has ...
... blood pressure measuring above the normal range (less than 120/80 ... strokes, or kidney disease. Lifestyle changes are the first-stage treatment ... , Many patients with high blood ... In so doing, many have consumed danshen, a Chinese herb ...
Cached Biology News:Cancer that colonizes our bodies 2New sensor detects gaseous chemical weapon surrogates in 45 seconds 2Active ingredient in common Chinese herb shown to reduce hypertension 2
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
SAPK/JNK Antibody...
Biology Products: